Viral infections as a cause of cancer (Review)

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1521-1528

  Carrillo Infante, C ^a,b   Abbadessa, G ^a,c   Bagella, L ^a,b,d   Giordano, A ^a,b  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF SIENA   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cancer; Epstein Barr virus; Hepatitis B virus; Hepatitis C virus; Human herpes virus 8; Human papilloma virus; Human T cell leukemia virus; Oncogene; Tumor virus

Indexed keywords

ANIMAL; HUMAN; NEOPLASM; PHYSIOLOGY; REVIEW; RISK FACTOR; TUMOR VIRUS; VIROLOGY; VIRUS CELL TRANSFORMATION; VIRUS INFECTION;

ANIMALS; CELL TRANSFORMATION, VIRAL; HUMANS; NEOPLASMS; ONCOGENIC VIRUSES; RISK FACTORS; TUMOR VIRUS INFECTIONS;

EID: 34447268958     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1521     Document Type: Review

References (96)

1. Gan DD, Macaluso M, Cinti C, Khalili K and Giordano A: How does a normal human cell become a cancer cell. J Exp Clin Cancer Res 4: 509-516, 2003. (Pubitemid 38222035)
2. Karakosta A, Golias Ch, Charalabopoulos A, Batistatou A and Charalabopoulos K: Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer: and chronic myelogenous and acute lymphoblastic leukaemia (review). J Exp Clin Cancer Res 24: 505-513, 2005.
3. Parkin DM: The global health burden of infection-associated cancers in the year 2002 (review). Int J Cancer 118: 3030-3044, 2006.
4. De Visser KE and Coussens LM: The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol Immunother 54: 1143-1152, 2005.
5. Campoli M, Ferrone S, Zea AH, Rodriguez PC and Ochoa AC: Mechanisms of tumor evasion. Cancer Treat Res 123: 61-88, 2005.
6. Hofseth LJ, Hussain SP, Wogan GN and Harris CC: Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 34: 955-968, 2003.
7. Lirk P, Hoffmann G and Rieder J: Inducible nitric oxide synthase-time for reappraisal. Curr Drug Targets Inflamm Allergy 1: 89-108, 2002.
8. Szabo C and Ohshima H: DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide 1: 373-385, 1997.
9. Mills KH: Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 4: 841-855, 2004.
10. + Tregs and immune control. J Clin Invest 114: 1209-1221, 2004.
11. + regulatory T cells control the severity of viral immuno-inflammatory lesions. J Immunol 172: 4123-4132, 2004.
12. Schottenfield D and Beebe-Dimmer JL: Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions. Ann Rev Public Health 26: 37-60, 2005.
13. Tyler KL and Fields BN: Pathogenesis of viral infections. In: Fields Virology. 3rd edition. Fields BN, Knipe DM and Howley PM (eds). Lippincott-Raven Publishers, Philadelphia, PA, pp173-203, 1996.
14. Beral V and Newton R: Overview of the epidemiology of immunodeficiency-associated cancers. Monogr Natl Cancer Inst 23: 1-6, 1998.
15. Newton R, Beral V and Weiss R: Human immunodeficiency virus infection and cancer. Cancer Surv 33: 237-262, 1999.
16. Nevins JF and Vogt PK: Cell transformation by viruses. In: Fields Virology. 3rd edition. Fields BN, Knipe DM and Howley PM (eds). Lippincott-Raven Publishers, Philadelphia, PA, pp301-335, 1996.
17. Hunter T: Cooperation between oncogenes. Cell 64: 249-270, 1991.
18. Yokota J and Sugimura T: Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes. FASEB J 7: 20-25, 1993.
19. Diehl V, Hauch P and Harris N: Hodgkin's disease. In: Cancer: Principles and Practice of Oncology. De Vita VT, Hellman S and Rosenberg SA (eds). Lippincott Williams & Wilkins, Philadelphia, PA, pp23-39, 2001.
20. Yarchoan R and Little RE: Immunosuppression-related malignancies. In: Cancer: Principles and Practice of Oncology. De Vita VT, Hellman S and Rosenberg SA (eds). Lippincott Williams & Wilkins, Philadelphia, PA, p2575, 2001.
21. Evans AS and Mueller NE: Viruses and cancer: causal associations. Ann Epidemiol 1: 71-92, 1990.
22. Hill AB: Environment and disease: association of causation? Proc R Soc Med 58: 295-300, 1965.
23. Papesch M and Watkins R: Epstein-Barr virus infectious mononucleosis. Clin Otolaryngol 26: 3-8, 2001.
24. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA and Pagano JS: Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 310: 1225-1230, 1984.
25. Su IJ and Chen JY: The role of Epstein-Barr virus in lymphoid malignancies. Crit Rev Oncol Hematol 26: 25-41, 1997. (Pubitemid 27339228)
26. Liebowitz D: Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 338: 1413-1421, 1998.
27. Jeannel D, Bouvier G and Huber A: Nasopharyneal carcinoma: an epidemiological approach to carcinogenesis. Cancer Surv 33: 125-155, 1999.
28. Raab-Traub N: Epstein-Barr virus, lymphoproliferative diseases and nasopharyngeal carcinoma. In: Microbes and Malignancy: Infection as a Cause of Human Cancers. Parsonnet J (ed). Oxford University Press, Oxford, UK, pp180-206, 1999.
29. Brooks LA, Crook T and Crawford DH: Epstein-Barr virus and lymphomas. Cancer Surv 33: 75-98, 1999.
30. Camilleri-Broct S, Camparo P, Mokhtari K, et al: Overexpression of Bcl-2, bcl-x and Bax in primary central nervous system lymphomas that occur in immunosuppressed patients. Mod Pathol 13: 158-165, 2000.
31. Wilson JB, Bell JL and Levine AJ: Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 15: 3117-3126, 1996.
32. Levitskaya J, Coram M, Levitsky V, et al: Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375: 685-688, 1995.
33. Abbot SD, Rowe M, Cadwallader K, et al: Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol 64: 2126-2134, 1990.
34. Zimber-Strobl U, Suentzenich KO, Laux G, et al: Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol 65: 425-423, 1991.
35. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J and Rickinson AB: Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 349: 612-614, 1991. (Pubitemid 21912115)
36. Laherty CD, Hu MM, Opipari AW, Wang F and Dixit VM: The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J Biol Chem 267: 24157-24160, 1992.
37. Mosialos G, Birkenbach M, Yalamanchili R, van Arsdale T, Ware C and Kieff E: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80: 389-399, 1995.
38. Eliopoulos AG, Stack M, Dawson CW, et al: Epstein-Barr virus encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via and NF-κB pathway involving TNF-receptor-associated factors. Oncogene 14: 2899-2916, 1997.
39. Eliopoulos AG and Young LS: Activation of the c-Jun N-terminal kinase (JNK) pathway by the Epstein-Barr virus encoded latent membrane protein-1. Oncogene 16: 1731-1742, 1998.
40. Gires O, Kohlhuber F, Kilger E, et al: Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 18: 3064-3073, 1999.
41. Zhao B and Sample CE: Epstein-Barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an Spi-1/Spi-B binding site. J Virol 74: 5151-5160, 2000.
42. Cheng G and Baltimore D: TANK, a co-inducer with TRAF2 of TNF- and CD40L-mediated NF-κB activation. Genes Dev 10: 963-973, 1996. (Pubitemid 26138707)
43. Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M and McKnight JL: Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 81: 1393-1403, 1993.
44. Bernard HU: The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 32: S1-S6, 2005.
45. IARC. Human papillomaviruses. Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 64. IARC, Lyon, pp1-378, 1995.
46. Munoz N, Bosch FX, De Sanjose S, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003. (Pubitemid 36159887)
47. Bovicelli A, D'Andrilli G and Giordano A: Multidisciplinary International Conference on Gynecologic Cancer, Bologna, Italy, June 8-12, 2005. J Cell Physiol 208: 1-5, 2006.
48. Clifford GM, Smith JS, Plummer M, Munoz N and Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73, 2003.
49. Fehrmann F and Laimins LA: Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22: 5201-5207, 2003. (Pubitemid 37059601)
50. Francis DA, Schmid SI and Howley PM: Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. J Virol 74: 2679-2686, 2000.
51. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.
52. Mythily DV, Krishna S and Tergaonkar V: Pleiotropic effects of human papillomavirus type 16. E6 oncogene expression in human epithelial cell lines. J Gen Virol 80: 1707-1713, 1999.
53. Klingelhutz AJ, Foster SA and McDougall JK: Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380: 79-82, 1996.
54. Dyson N: The regulation of E2F by Rb-family proteins. Genes Dev 12: 2245-2262, 1998.
55. Cage JR, Meyers C and Wettstein FO: The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J Virol 64: 723-730, 1990. (Pubitemid 20032688)
56. Imai Y, Matsushima Y, Sugimura T and Terrada M: Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product. J Virol 65: 4966-4972, 1991.
57. Di Maio D, Lai CC and Klein O: Virocrine transformation: the intersection between viral transforming proteins and cellular signal transduction pathways. Annu Rev Microbiol 52: 397-421, 1998.
58. Villa LL, Costa RL, Petta CA, et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine in young women: a randomized double-blind placebo-controlled multicenter phase II efficacy trial. Lancet Oncol 6: 271-278, 2005.
59. Harper DM, Franco EL, Wheeler CM, et al: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367: 1247-1255, 2006.
60. IARC Hepatitis viruses. Monographs on the Evaluation of Carcinogenic Risks. Vol. 59. IARC, Lyon, 1994.
61. Fattovich G, Stroffolini T, Zagni I and Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127: S27-S34, 2004.
62. Buendia MA: Hepatitis B viruses and hepatocellular carcinoma. Adv Cancer Res 59: 167-226, 1992.
63. Hollinger FF: Hepatitis B virus. In: Fields Virology 3rd. Vol. 2. Fields GN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B and Straus SE (eds). Lippincott-Raven, Philadelphia PA, pp2739-2807, 1990.
64. Hino O, Tabata S and Hotta Y: Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc Natl Acad Sci USA 88: 9248-9252, 1991.
65. Paterlini-Brechot P, Saigo K, Murakami Y, et al: Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22: 3911-3916, 2003.
66. Dejean A, Bougueleret L, Grzeschik KH and Tiollais P: Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature 322: 70-72, 1986.
67. Slagle BL, Zhou YZ and Butel JS: Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas. Cancer Res 51: 49-54, 1991.
68. Matsubara K and Tokino T: Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med 7: 243-260, 1990. (Pubitemid 20283937)
69. Robinson WS: Hepatitis B virus and hepatocellular carcinoma. In: Microbes and Malignancy: Infection as a Cause of Human Cancers. Parsonnet J (ed). Oxford University Press, Oxford, pp232-266, 1999.
70. Natoli G, Avantaggiati ML, Chirillo P, et al: Modulation of intracellular signal transduction pathways by the hepatitis B virus transactivator pX. J Hepatol 22: 14-20, 1995.
71. Lee YH and Yun Y: HBx protein of hepatitis B virus activates Jak1-STAT signaling. J Biol Chem 273: 25510-25515, 1998. (Pubitemid 28443322)
72. Diao J, Khine AA, Sarangi F, et al: X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway. J Biol Chem 276: 8328-8340, 2001.
73. Lee YI, Kang-Park S, Do SI and Lee YI: The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 276: 16969-16977, 2001.
74. Edamoto Y, Hara A, Biernat W, et al: Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 106: 334-341, 2003.
75. Bréchot C: Hepatitis C virus: molecular biology and genetic variability. In: Acute and Chronic Liver Diseases. Schmid R (ed). Kluwer Academic Publishers, Basel, pp35-57, 1996.
76. Ferns X, Purcell RH and Burkh J: Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol 7: 402-410, 1999.
77. Alter MJ, Kruszon-Moran D, Nainan OV, et al: The prevalence of hepatitis C virus infection in the United States. 1988 through 1994. N Engl J Med 341: 556-562, 1999.
78. Alisi A, Mele R, Spaziani A, Tavolaro S, Palescandolo E and Balsano C: Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells. J Cell Biol 205: 25-31, 2005. (Pubitemid 41262847)
79. Dupin N, Fisher C, Kellam P, et al: Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 96: 4546-4551, 1999.
80. Xchulz TF: Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J Gen Virol 79: 1573-1591, 1998.
81. Cohen A, Wolf DG, Guttman-Yassky E and Sarid R: Kaposi's sarcoma-associated herpesvirus: clinical, diagnostic, and epidemiological aspects. Crit Rev Clin Lab Sci 42: 101-103, 2005.
82. Antman K and Chang Y: Kaposi's sarcoma. N Engl J Med 342: 1027-1038, 2000.
83. Ballestas ME, Chatis PA and Kaye KM: Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 71: 641-644, 1999.
84. Pati S, Cavrois M, Guo HG, Foulke JS Jr, Kim J, Feldman RA and Reitz M: Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J Virol 75: 8660-8673, 2001. (Pubitemid 32768970)
85. Cheng EH, Nicholas J, Bellows DS, Hayward GS and Guo HG: A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci USA 94: 690-694, 1997.
86. Burger M, Hartmann T, Burger JA and Schraufstatter I: KSHV-vGPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene 24: 2067-2075, 2005.
87. Dadke D, Fryer BH, Golemis EA and Field J: Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. Cancer Res 63: 8837-8847, 2003.
88. Gallo RC: The first human retrovirus. Sci Am 255: 88-98, 1986.
89. Hinuma Y, Nagata K, Hanaoka M, et al: Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 78: 6476-6480, 1981.
90. Kashiwagi K, Furusyo N, Nakashima H, Kubo N, Kinukawa N, Kashiwagi S and Hayashi J: A decrease in mother-to-child transmission of human T lymphotropic virus type I (HTLV-1) in Okinawa, Japan. Am J Trop Med Hyg 70: 158-163, 2004. (Pubitemid 38200520)
91. Matsuoka M: Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 22: 5131-5140, 2003.
92. Alefantis T, Barmak K, Harhaj EW, Grant C and Wigdahl B: Characterization of a nuclear export signal within the human T cell leukemia virus type I transactivator protein Tax. J Biol Chem 278: 21814-21822, 2003.
93. Grassmann R, Aboud M and Jeang KT: Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 24: 5976-5985, 2005.
94. Baeuerle PA and Baltimore D: NF-κB: Ten years after. Cell 87: 13-20, 1996.
95. Haller K, Wu Y, Derow E, Schmitt I, et al: Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein. Mol Cell Biol 22: 3327-3338, 2002.
96. Giordano A, Galderisi U and Marino IR: From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 211: 27-35, 2007. (Pubitemid 46363893)